To hear about similar clinical trials, please enter your email below
Trial Title:
Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer Patients
NCT ID:
NCT05837533
Condition:
Breast Cancer Stage IV
Breast Cancer Metastatic
Communication
Conditions: Official terms:
Breast Neoplasms
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
Non-Randomized
Intervention model:
Sequential Assignment
Intervention model description:
During the first half of the study, patients will be assigned to the control group where
they will receive information through their usual care from their oncologist during their
medical consultation. In the second half of the study, patients will be assigned to the
intervention group where they will receive information through the communication model
used by their oncologist during their medical consultation. In this way, the
contamination of the control group with attention corresponding to the systematized
communication model under study will be avoided.
Primary purpose:
Other
Masking:
Double (Participant, Outcomes Assessor)
Masking description:
Participants will not be informed whether they will be allocated to the control or
intervention group.
Intervention:
Intervention type:
Other
Intervention name:
Communication model
Description:
During the medical consultation of each patient assigned to the intervention group, the
oncologist will use the systematic communication model for patients with metastatic
breast cancer. For this, the oncologist will follow the conversation guide for patients
with metastatic breast cancer, which will allow directing the conversation towards
information about the patient's diagnosis, treatment and prognosis. The guide consists of
a series of steps and questions to be asked to the patient in order to explore her
understanding of her disease and her information preferences, as well as to facilitate
the oncologist providing said information to the patient. The responses to each item in
the guide will be electronically documented by the oncologist.
Arm group label:
Intervention group
Summary:
Both in Mexico and in the world, breast cancer is the most common malignancy in women. It
is estimated that in 2020, 28.2% of the new cancer cases reported in our country
correspond to breast cancer, which translates to 30,000 new cases. In addition, it is
relevant to mention that approximately 12% of Mexican patients are diagnosed with stage
IV breast cancer and it is estimated that 20-30% of women with early stage cancer will
have a distant recurrence of the disease. Thus, about 40% of patients will find
themselves in a metastatic stage at some point in their breast cancer journey.
Various studies, including Mexico, report that only half of patients with metastatic
breast cancer are aware that their disease is not curable, 31% say they are not sure, and
17% think it is curable. Likewise, 58% considered that they did not have enough knowledge
to actively participate in conversations about their therapeutic options, which means
that 40% reported difficulty talking about treatments with their doctors. This has shown
that there are suboptimal levels of knowledge information on curability, treatment
objectives and prognosis of their condition in patients with metastatic breast cancer.
This lack of understanding is alarming given that a general understanding of the disease
is crucial for informed decision making and adherence to cancer treatment.
Due to these alarming results, we seek to recruit women ≥18 years of age who are
candidates to start first- or second-line treatment for de novo or recurrent metastatic
breast cancer from various hospital centers in the country with public and private
coverage, including Hospital Zambrano Hellion TecSalud as coordinating center in Nuevo
León. The objective will be to evaluate whether a systematized communication model for
patients with metastatic breast cancer allows increasing knowledge about the non-curative
nature of treatment, compared to usual care.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Diagnosis of de novo or recurrent metastatic breast cancer
- Candidate to start the first or second line of treatment for metastatic breast
cancer
Exclusion Criteria:
- Receipt of a line of treatment for metastatic breast cancer posterior to the second
line
Gender:
Female
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Hospital Zambrano Hellion
Address:
City:
San Pedro Garza Garcia
Zip:
66278
Country:
Mexico
Status:
Recruiting
Contact:
Last name:
Cynthia Villarreal-Garza, MD, DSc
Start date:
May 17, 2023
Completion date:
June 2025
Lead sponsor:
Agency:
Medicos e Investigadores en la Lucha contra el Cancer de Mama
Agency class:
Other
Source:
Medicos e Investigadores en la Lucha contra el Cancer de Mama
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05837533